Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
Phase of Trial: Phase I
Latest Information Update: 21 Jul 2011
At a glance
- Drugs Moxifloxacin; Vildagliptin
- Indications Bacterial infections; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals Corporation
- 21 Jul 2011 New trial record
- 24 May 2011 Results published in the Current Medical Research and Opinion.